Blocking IFNAR1 inhibits multiple myeloma–driven Treg expansion and immunosuppression
Authors:
- Yawara KawanoYKYawara Kawano
- Oksana ZavidijOZOksana Zavidij
- Jihye ParkJPJihye Park
- Michele MoschettaMMMichele Moschetta
- Katsutoshi KokubunKKKatsutoshi Kokubun
- Tarek H. MouhieddineTMTarek H. Mouhieddine
- Salomon ManierSMSalomon Manier
- Yuji MishimaYMYuji Mishima
- Naoka MurakamiNMNaoka Murakami
- Mark BustorosMBMark Bustoros
- Romanos Sklavenitis PistofidisRPRomanos Sklavenitis Pistofidis
- Mairead ReidyMRMairead Reidy
Open Access
- 14 May 2018
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 128 (6) , 2487-2499
Abstract
Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One of the major immunosuppressive mechanisms that is believed to play a role in myeloma progression is the expansion of regulatory T cells (Tregs). In this study, we demonstrate that myeloma cells drive Treg expansion and activation by secreting type 1 interferon (IFN). Blocking IFN α and β receptor 1 (IFNAR1) on Tregs significantly decreases both myeloma-associated Treg immunosuppressive function and myeloma progression. Using syngeneic transplantable murine myeloma models and bone marrow (BM) aspirates of MM patients, we found that Tregs were expanded and activated in the BM microenvironment at early stages of myeloma development. Selective depletion of Tregs led to a complete remission and prolonged survival in mice injected with myeloma cells. Further analysis of the interaction between myeloma cells and Tregs using gene sequencing and enrichment analysis uncovered a feedback loop, wherein myeloma-cell-secreted type 1 IFN induced proliferation and expansion of Tregs. By using IFNAR1-blocking antibody treatment and IFNAR1-knockout Tregs, we demonstrated a significant decrease in myeloma-associated Treg proliferation, which was associated with longer survival of myeloma-injected mice. Our results thus suggest that blocking type 1 IFN signaling represents a potential strategy to target immunosuppressive Treg function in MM.Keywords
This publication has 61 references indexed in Scilit:
- Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balanceBlood Cancer Journal, 2013
- Expression profiles of human interferon‐alpha and interferon‐lambda subtypes are ligand‐ and cell‐dependentImmunology & Cell Biology, 2012
- The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammationNature Immunology, 2009
- Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control TH2 responsesNature, 2009
- AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center MalignanciesCancer Cell, 2008
- CCR7 is required for the in vivo function of CD4+ CD25+ regulatory T cellsJournal of Experimental Medicine, 2007
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005
- IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon inductionNature Immunology, 2005
- Toll-like receptor control of the adaptive immune responsesNature Immunology, 2004